• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Innoviva-GSK project Trelegy Ellipta meets main endpoint in asthma pivotal trial

May 6, 2019 By Brad Perriello

GlaxoSmithKline, Innoviva, Trelegy ElliptaA combination drug-device therapy developed by GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) for asthma, Trelegy Ellipta, met the primary endpoint in its pivotal trial, the companies said last week.

The Trelegy Ellipta inhaler is designed to deliver a single daily dose of three drugs – fluticasone furoate, umeclidinium and vilanterol – to patients with uncontrolled asthma. The 2,436-patient Captain trial compared Trelegy Ellipta with Relvar/Breo Ellipta, consisting of just fluticasone furoate.  The study was randomized, double-blinded and active-controlled along six parallel treatment arms with roughly 400 patients in each, the companies said, involving Trelegy Ellipta at two doses and Relvar/Breo at two doses.

The primary endpoint was change in trough Forced Expiratory Volume in 1 second (FEV1) at 24 weeks, with a secondary endpoint of annual rate of moderate/severe asthma exacerbations. The trial showed a statistically significant lung function improvements for both Trelegy Ellipta dosage formulations compared with the corresponding Relvar/Breo treatments.

But the study failed to meet the secondary endpoint, showing a statistically insignificant 13% reduction in exacerbations. Adverse event rates were similar across all six arms, they said, with nasopharyngitis at 13% to 15%, headache at 5% to 9%, upper respiratory tract infection at 3% to 6% and bronchitis at 3% to 5%.

“We believe a once-daily single inhaler triple therapy that improves lung function is an advance for patients with uncontrolled asthma since this option is not currently available. We plan to submit these data for regulatory review after the full dataset is available,” GSK president & CSO Dr. Hal Barron said in prepared remarks.

“The Captain study has shown that triple therapy in a single inhaler provides a potential new treatment option for asthma management in patients uncontrolled on ICS/LABA,” added Innoviva respiratory medicine VP Paul Meunier.

The companies said full results from the trial are slated to be released at coming scientific meetings and via peer-reviewed journals.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: GlaxoSmithKline plc, Innoviva

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS